JAK Inhibitors in Atopic Dermatitis: 2024 Update
Janus kinase (JAK) inhibitors represent a significant paradigm shift in the management of moderate-to-severe atopic dermatitis, offering rapid itch relief and high efficacy.
Mechanism of Action
JAK inhibitors block the intracellular signaling pathways of multiple key cytokines involved in atopic dermatitis pathogenesis, including IL-4, IL-13, IL-31 (the "itch cytokine"), and TSLP.
Available Agents
| Drug | Target | Formulation | Key Indication |
|---|---|---|---|
| Upadacitinib (Rinvoq) | JAK1 selective | Oral | Severe AD (Adults & Adolescents 12+) |
| Abrocitinib (Cibinqo) | JAK1 selective | Oral | Severe AD (Adults & Adolescents 12+) |
| Baricitinib (Olumiant) | JAK1 / JAK2 | Oral | Severe AD (Adults) |
| Ruxolitinib (Opzelura) | JAK1 / JAK2 | Topical Cream | Mild to Mod AD (Short-term use) |
Safety Profile and Black Box Warnings
Oral JAK inhibitors carry class-wide warnings based on data primarily derived from older rheumatoid arthritis patients taking Tofacitinib. Warnings include:
- Increased risk of serious cardiovascular events (MACE).
- Increased risk of venous thromboembolism (DVT/PE).
- Increased risk of serious infections (particularly Herpes Zoster / Shingles).
- Increased risk of certain malignancies (lymphoma).
Prescribing requires careful patient selection, avoiding use in patients over 65, those with cardiovascular risk factors, or a history of VTE or malignancy unless no suitable alternatives exist.